

Figures

1.1	Percentage of invasive isolates tested resistant to selected antibiotics for <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> reported from European countries in 2017	page 3
1.2	Cross country comparison of patterns of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> resistant to third-generation cephalosporins	5
2.1	Relative risk of 30-day mortality of patients with resistant infections relative to those with susceptible infections	24
2.2	Cost of hospitalization for patients with <i>Escherichia coli</i> antibiotic-resistant infection and underlying drivers	34
2.3	Projected working-age population loss in OECD countries per year relative to 0% resistance, 2020–2050	36
4.1	Relationship between the number of hospital-acquired infections and investments in infection control	75
5.1	Summary of the pathways of transmission of resistant bacteria between animals, humans and the environment	104
5.2	Different routes for exchange of resistant bacteria or genes from animals to humans and vice versa	112
6.1	Number of new classes of antibiotic discovered or patented each decade	126
6.2	The number of antibiotics in clinical development possibly active against WHO PPL pathogens (2017) and the number of alternative therapies to antibiotics in clinical development (2017)	128
6.3	Framework for developing a holistic incentive package for antibiotic development	134
6.4	Continuum of incentivization across the antibiotic value chain	142
8.1	Ways in which vaccines may reduce antimicrobial resistance	183

9.1	Systems diagram of the challenge of antimicrobial resistance	211
9.2	“A Fair Shot” pictograph by the Médecins sans Frontières Access Campaign	219
9.3	Dutch Minister of Health, Welfare and Sport, Edith Schippers, poses for photo with US Public Interest Research Group at 2016 UN General Assembly	227
9.4	Book on microbes by children for children from ReAct Latin America	231